Safety of bevacizumab in patients younger than 4 years of age

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
N C MillanJ Mora

Abstract

Limited data exist regarding the safety and efficacy of bevacizumab in pediatric patients under the age of 4 years. Here, we report a large cohort of pediatric patients under 4 years of age treated with bevacizumab. The primary objective was to document adverse events with a possible relationship to bevacizumab. Patients (n = 16) were identified through retrospective chart review and harbored a variety of conditions (44% central nervous system (CNS) tumors, 31% vascular anomalies, 13% neuroblastoma, 12% other). The median age was 34.3 months (range 4.9-47.3), including five patients <2 years of age. Patients received bevacizumab for a median duration of 6.2 months, alone or with chemotherapy, and a median dose of 9.25 mg/kg (range 7.0-11.8). Partial responses were seen in 19% of patients, and clinical improvements were seen in 69%. Adverse events known to be associated with bevacizumab occurred in 37%. Outcomes observed in this population resemble those reported for bevacizumab in older pediatric patients. The overall pattern and frequency of adverse events observed was similar to those seen in reports of older pediatric patients with a variety of conditions. The highest level of efficacy observed was seen among patients with v...Continue Reading

References

Jul 12, 2011·Pediatric Blood & Cancer·Nuria CondeJaume Mora
Nov 1, 2011·Journal of Neurosurgery·Ashwatha NarayanaMichael L Gruber
Nov 2, 2011·The Oncologist·Julia Glade BenderElizabeth Fox
Jan 10, 2012·Cold Spring Harbor Perspectives in Medicine·Shoshana Greenberger, Joyce Bischoff
Jun 28, 2012·Journal of Pediatric Hematology/oncology·Emilia HintsalaSanna-Maria Kivivuori
Sep 1, 2012·Anti-cancer Agents in Medicinal Chemistry·Michael L MegisonElizabeth A Beierle
Nov 13, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Fariba NavidVictor M Santana
Jan 9, 2013·Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery·Dolly AguileraRobert C Castellino
Oct 12, 2013·Pediatric Blood & Cancer·Rajkumar VenkatramaniLeo Mascarenhas
Nov 16, 2013·JAMA Ophthalmology·Robert A AveryRoger J Packer
Dec 7, 2013·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Agnes D Berendsen, Bjorn R Olsen

❮ Previous
Next ❯

Citations

Oct 26, 2016·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Magali HernandezDominique Droz
Nov 1, 2018·Pediatric Blood & Cancer·Hermann L MüllerSabine Fürst-Recktenwald
Jan 30, 2018·Asia-Pacific Journal of Ophthalmology·Kimberly D TranAudina M Berrocal

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies
S GrossoP Balestri
The Pediatric Infectious Disease Journal
David W KimberlinNIAID Collaborative Antiviral Study Group
© 2021 Meta ULC. All rights reserved